Saturday 17 October 2026
Export SRPT’s income statement to Excel — free account
Sarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
17.06
0.73
−4.10%
Follow SRPT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 5 | 5 | 2 | 3 | 6 | 2 | 2 | 3 | 5 |
P/E ratio |
0.00 | 49.63 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(0.97) | 2.73 | 1.13 | 1.21 | 1.11 | 2.64 | 3.64 | 6.18 | 3.21 | 4.10 |
P/S ratio |
0.98 | 6.08 | 7.15 | 11.72 | 10.43 | 24.61 | 24.94 | 24.02 | 22.16 | 139.35 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 99.68 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(2.78) | 1.44 | (0.75) | (1.01) | 0.62 | 0.53 | (1.52) | 2.24 | 3.40 | (4.54) |
P/Operating CF |
16.42 | 125.59 | (162.64) | (118.31) | (249.53) | (76.15) | (57.99) | (59.06) | (110.31) | (16.74) |
Beneish M-Score |
(3.41) | (1.39) | (1.73) | (2.80) | (1.97) | (3.32) | (2.41) | (0.70) | 21.77 | (0.27) |
P/B ratio |
1.89 | 7.57 | 10.34 | 28.40 | 7.89 | 17.45 | 11.61 | 7.00 | 4.34 | 4.04 |
Price to Tangible BV |
1.91 | 7.63 | 10.50 | 29.39 | 8.01 | 17.77 | 11.79 | 7.08 | 4.42 | 4.14 |
EV/Sales |
0.97 | 6.01 | 6.80 | 11.25 | 9.00 | 22.90 | 23.80 | 21.55 | 17.97 | 107.33 |
EV/EBITDA |
0.00 | 53.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(10.39) | (55.56) | (16.87) | (32.28) | (14.25) | 115.07 | (19.86) | (16.69) | (11.97) | (4.26) |
EV/FCF |
(6.77) | (32.41) | (17.38) | (29.18) | (16.53) | 92.74 | (17.45) | (14.32) | (21.67) | (4.14) |
Quick Ratio |
1.22 | 2.67 | 3.18 | 3.56 | 5.01 | 4.90 | 4.59 | 7.04 | 12.55 | 4.43 |
Current Ratio |
2.32 | 4.20 | 3.95 | 4.13 | 5.75 | 5.97 | 5.55 | 8.21 | 13.91 | 4.95 |
Net Debt/EBITDA |
0.17 | (1.01) | 1.63 | 0.85 | 2.38 | 1.72 | 0.64 | 2.22 | 3.94 | 1.20 |
Debt/Assets |
24.75% | 28.69% | 37.92% | 49.84% | 35.32% | 33.96% | 37.85% | 25.61% | 32.96% | 3.81% |
Debt/Equity |
0.73 | 0.74 | 1.44 | 4.05 | 1.20 | 1.33 | 0.84 | 0.41 | 0.55 | 0.05 |
Asset Turnover |
0.60 | 0.53 | 0.39 | 0.30 | 0.23 | 0.22 | 0.22 | 0.20 | 0.18 | 0.02 |
Operating CF/Net income |
0.29 | (0.87) | 0.93 | 0.46 | 1.06 | (0.19) | 0.64 | 1.07 | 4.58 | 0.92 |
Capex/Depreciation |
(2.80) | 57.56 | (8.24) | (1.03) | 1.61 | 0.96 | (2.43) | (13.37) | 14.41 | (1.21) |
Interest Coverage |
— | — | — | (19.34) | (899.63) | (75.64) | (31.24) | (22.34) | (94.88) | (498.56) |
| (53.47%) | 19.71% | (86.15%) | (107.16%) | (49.57%) | (70.15%) | (77.29%) | (39.74%) | (9.00%) | (101.42%) | |
| (19.51%) | 6.51% | (16.77%) | (22.42%) | (13.66%) | (23.05%) | (41.28%) | (24.54%) | (5.85%) | (76.59%) | |
ROIC |
(42.46%) | 10.40% | (39.75%) | 0.00% | 0.00% | 0.00% | (115.04%) | (77.00%) | (75.97%) | (686.01%) |
Return on Tangible Assets |
(39.90%) | 8.77% | (24.90%) | (33.21%) | (17.88%) | (24.52%) | (53.61%) | (26.82%) | (4.28%) | (79.58%) |
Average Days of Receivables |
66.12 | 115.52 | 117.52 | 83.96 | 79.56 | 68.49 | 87.10 | 59.47 | 69.58 | 352.01 |
Research and Development Expense of Revenue |
69.24% | 42.30% | 70.57% | 94.01% | 109.87% | 133.74% | 147.28% | 133.49% | 107.84% | 3,473.01% |
Selling, General and Administrative Expense of Revenue |
22.37% | 29.33% | 38.76% | 48.38% | 40.27% | 58.85% | 74.79% | 69.02% | 79.36% | 1,544.90% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.02 |
Share Based Compensation of Revenue |
5.61% | 9.69% | 14.68% | 24.97% | 16.23% | 20.01% | 20.64% | 16.65% | 19.71% | 552.70% |
Graham Net Nets |
0.15 | 0.06 | 0.02 | (0.02) | 0.05 | 0.02 | 0.05 | 0.11 | 0.21 | 0.21 |
Graham Number |
0.00 | 29.76 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(33.15%) | 2.01% | (6.34%) | (6.43%) | (5.71%) | (4.14%) | (7.49%) | (4.97%) | (1.32%) | (19.56%) |
Free Cash Flow Yield |
(14.64%) | (3.05%) | (5.47%) | (3.29%) | (5.22%) | 1.00% | (5.47%) | (6.27%) | (3.74%) | (18.59%) |
Revenue per Share |
21.96 | 20.01 | 13.46 | 10.66 | 8.64 | 6.93 | 5.17 | 4.54 | 2.63 | 0.11 |
Operating CF per Share |
(2.05) | (2.16) | (5.42) | (3.72) | (5.45) | 1.38 | (6.20) | (5.87) | (3.94) | (5.05) |
Capex per Share |
(1.10) | (1.55) | 0.16 | (0.37) | 0.75 | 0.33 | (0.81) | (0.92) | 1.76 | (0.14) |
Free Cash Flow per Share |
(3.15) | (3.71) | (5.26) | (4.08) | (4.70) | 1.71 | (7.01) | (6.79) | (2.18) | (5.19) |
Cash per Share |
9.39 | 14.25 | 18.14 | 22.72 | 26.04 | 24.87 | 15.28 | 17.72 | 18.35 | 6.75 |
Shareholders Equity per Share |
11.39 | 16.07 | 9.30 | 4.40 | 11.42 | 9.77 | 11.11 | 15.58 | 13.42 | 6.91 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
11.39 | 16.07 | 9.30 | 4.40 | 11.42 | 9.77 | 11.11 | 15.58 | 13.42 | 6.91 |
Free Cash Flow |
(315.33) | (352.74) | (486.34) | (357.60) | (381.97) | 133.33 | (516.09) | (449.82) | (128.21) | (252.69) |
Working Capital |
1,442.65 | 2,341.78 | 1,925.67 | 1,938.26 | 2,151.37 | 2,069.17 | 1,204.15 | 1,252.49 | 1,140.31 | 298.05 |
Capital Expenditures |
(109.85) | (146.96) | 14.66 | (32.25) | 61.20 | 25.87 | (59.63) | (61.16) | 103.79 | (6.87) |
Net Current Asset Value |
328.86 | 638.03 | 174.09 | (185.55) | 384.13 | 262.24 | 464.28 | 816.38 | 709.90 | 286.06 |
EV/EBIT |
0.00 | 52.43 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.05 | 0.08 | (0.01) | 0.03 | (0.09) | (0.05) | 0.16 | 0.20 | (0.67) | 1.27 |
Price to Operating Income |
0.00 | 53.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.11 | (0.01) | (0.01) | 0.17 | 0.20 | 0.14 | 0.19 | 0.05 | 0.17 | 0.15 |
Cash ROIC |
(10.84%) | (8.78%) | (12.89%) | (9.09%) | (9.19%) | 3.59% | (19.60%) | (17.12%) | (5.58%) | (37.08%) |
Accounts Receivable Turnover |
4.40 | 3.80 | 4.04 | 5.08 | 5.52 | 5.62 | 5.44 | 7.67 | 8.91 | 1.18 |
Accounts Payable Turnover |
3.39 | 1.68 | 1.15 | 1.62 | 1.03 | 0.71 | 1.11 | 1.62 | 0.39 | 0.00 |
Inventory Turnover |
1.01 | 0.59 | 0.57 | 0.72 | 0.46 | 0.31 | 0.38 | 0.33 | 0.15 | 0.00 |
Average Days of Payables |
122.09 | 245.29 | 400.38 | 249.98 | 288.62 | 639.74 | 439.23 | 361.11 | 420.30 | 107,295.54 |
Days of Inventory on Hand |
397.67 | 857.84 | 783.83 | 531.82 | 700.34 | 1,335.80 | 1,105.46 | 1,339.09 | 4,150.12 | 46,304.41 |
Average Receivables |
500.11 | 501.16 | 307.48 | 183.81 | 127.17 | 96.11 | 69.96 | 39.26 | 17.35 | 4.60 |
Average Payables |
247.64 | 189.68 | 130.40 | 86.31 | 93.92 | 89.59 | 50.96 | 21.15 | 19.08 | 24.96 |
Average Inventory |
832.35 | 536.41 | 263.41 | 195.09 | 209.09 | 201.67 | 148.41 | 104.53 | 48.21 | 48.41 |
Average Assets |
3,656.44 | 3,613.87 | 3,196.47 | 3,138.17 | 3,066.35 | 2,403.77 | 1,732.45 | 1,475.02 | 866.03 | 348.94 |
Average Common Equity |
1,334.18 | 1,193.54 | 622.14 | 656.48 | 844.88 | 789.97 | 925.23 | 910.75 | 562.95 | 263.52 |
Columns are period end dates